Improving Lives
Focusing on the development and commercialisation of neurological solutions
Exclusive worldwide licence
Extensive preclinical studies completed
Neurotech’s Mente device and therapy
Paediatric Focus
Potential for NTI164 to treat neurological disorders
PCT Patents lodged
Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).
The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.
Bioshares Report
Now Available
Neurotech International (NTI: $0.071) has released the results from its Phase II study in children with moderate autism spectrum disorder (ASD). The study involved 14 children who were treated with lead drug candidate, NTI164.
Latest Announcements
Latest News
